Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference. Together, they explore the latest data on Retatrutide's potential to deliver bariatric surgery-level weight loss, improve cardiometabolic health, and reshape the future of obesity and type 2 diabetes treatment.

otplinks.com

Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel Skowronski, who suggested that obesity could become a solved disease within just a few generations of innovation.

What does that mean for the millions of patients still fighting for access to GLP-1 medications like Zepbound, Mounjaro, and tirzepatide? And what is Lilly seeing in its pipeline that the rest of us can't?

We dig into:

• Lilly's decision to stop disclosing its Phase 1 pipeline
• The Camurus fluid crystal technology deal and what it means for long-acting GLP-1s
• Eloralintide — Lilly's selective amylin agonist and potential dark horse in obesity medicine
• How eloralintide compares to Novo Nordisk's cagrilintide
• Why the future of obesity treatment is a toolbox, not a scoreboard
• The access crisis: prior authorizations, insurance exclusions, Medicare, and Medicaid coverage gaps
• Retatrutide, quintuple agonists, and what's coming out of ADA 2026

If you're on Zepbound, Wegovy, Ozempic, or any GLP-1 medication — or you're waiting for the next generation of obesity drugs — this episode is for you.

🔔 Subscribe for weekly updates on obesity medicine, GLP-1 news, and what it all means for patients.

💊 Sponsored by Shed — visit TryShed.com and use code OTP25 to save 25% on obesity care.